La Jolla Pharmaceutical Company to Present at BIO CEO & Investor Conference

La Jolla Pharmaceutical Company (Nasdaq: LJPC) today announced that Deirdre Y. Gillespie, M.D., President and Chief Executive Officer, will present on Monday, February 9, at 11:00 a.m. Eastern Time during the BIO CEO Investor Conference. The conference will take place at The Waldorf=Astoria Hotel in New York City. An audio web cast of the presentation will be available through the Company’s Web site: http://www.ljpc.com.

About La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company is dedicated to improving and preserving human life by developing innovative pharmaceutical products. The Company’s leading product in development is Riquent^®, which is designed to treat lupus renal disease by preventing or delaying renal flares. Lupus renal disease is a leading cause of sickness and death in patients with lupus. The Company has also developed potential small molecule drug candidates to treat various other autoimmune and inflammatory conditions. The Company's common stock is traded on The Nasdaq Global Market under the symbol LJPC. More information about the Company is available on its Web site: http://www.ljpc.com.

This press release and the presentations may contain forward-looking statements within the meaning of the federal securities laws. When used, the words "anticipate,” "assume,” "believe,” "estimate,” "expect,” "intend,” "may,” "plan,” "project,” "result,” "should,” "will” and similar expressions that do not relate solely to historical matters identify forward-looking statements. Forward-looking statements are subject to risks and uncertainties, both known and unknown and often beyond the Company’s control, and are not guarantees of future performance insofar as actual events or results may vary materially from those anticipated. Factors that may cause such a variance consist of, among others, those discussed from time to time in the Company’s filings with the Securities and Exchange Commission, including the risks described in "Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2007, subsequent quarterly reports on Form 10-Q, and specifically the Company’s ability to: demonstrate sufficiently Riquent’s efficacy and safety in clinical trials; obtain additional funding; manufacture Riquent on an adequate scale for clinical use; or develop further and commercialize Riquent successfully, either on its own or with a partner. The Company expressly disclaims any responsibility to update forward-looking statements.